278 related articles for article (PubMed ID: 27695345)
21. Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma.
Habashy S; Jafri A; Osman HO; Thomas NE; Udekwe S; Heindl SE
Cureus; 2021 Mar; 13(3):e13859. PubMed ID: 33754119
[TBL] [Abstract][Full Text] [Related]
22. Strategies to target the Hedgehog signaling pathway for cancer therapy.
Xin M; Ji X; De La Cruz LK; Thareja S; Wang B
Med Res Rev; 2018 May; 38(3):870-913. PubMed ID: 29315702
[TBL] [Abstract][Full Text] [Related]
23. Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.
Fania L; Didona D; Morese R; Campana I; Coco V; Di Pietro FR; Ricci F; Pallotta S; Candi E; Abeni D; Dellambra E
Biomedicines; 2020 Oct; 8(11):. PubMed ID: 33113965
[TBL] [Abstract][Full Text] [Related]
24. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
[TBL] [Abstract][Full Text] [Related]
25. Emerging drugs and combination strategies for basal cell carcinoma.
Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
[TBL] [Abstract][Full Text] [Related]
26. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
[TBL] [Abstract][Full Text] [Related]
27. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
28. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R
Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810
[TBL] [Abstract][Full Text] [Related]
29. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
30. Expression of Glioma-associated oncogene homolog 1 as biomarker with sonidegib in advanced basal cell carcinoma.
Dummer R; Liu L; Squittieri N; Gutzmer R; Lear J
Oncotarget; 2020 Sep; 11(37):3473-3483. PubMed ID: 32973971
[TBL] [Abstract][Full Text] [Related]
31. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
32. Emerging trends in the treatment of advanced basal cell carcinoma.
Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
[TBL] [Abstract][Full Text] [Related]
33. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
34. Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data.
Nazzaro G; Benzecry V; Mattioli MA; Denaro N; Beltramini GA; Marzano AV; Passoni E
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509282
[TBL] [Abstract][Full Text] [Related]
35. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
36. Can hair re-growth be considered an early clinical marker of treatment resistance to Hedgehog inhibitors in patients with advanced basal cell carcinoma? A report of two cases.
Soura E; Plaka M; Dessinioti C; Syrigos K; Stratigos AJ
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1726-1729. PubMed ID: 27461144
[TBL] [Abstract][Full Text] [Related]
37. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma.
Mathis J; Doerr T; Lin E; Ibrahim SF
Dermatol Surg; 2019 Jan; 45(1):17-25. PubMed ID: 30586344
[TBL] [Abstract][Full Text] [Related]
38. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Rudnick EW; Thareja S; Cherpelis B
Int J Dermatol; 2016 Mar; 55(3):249-58; quiz 256, 258. PubMed ID: 26566923
[TBL] [Abstract][Full Text] [Related]
39. The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area.
Villani A; Fabbrocini G; Micali G; Fornaro L; Potestio L; Scalvenzi M
Dermatol Ther (Heidelb); 2023 Sep; 13(9):2121-2126. PubMed ID: 37477769
[TBL] [Abstract][Full Text] [Related]
40. Differential pharmacology and clinical utility of sonidegib in advanced basal cell carcinoma.
Wahid M; Jawed A; Dar SA; Mandal RK; Haque S
Onco Targets Ther; 2017; 10():515-520. PubMed ID: 28182134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
